Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT04958772

Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers

Clinical Trials Phase I, Single-Centric, Open, Randomized, Crossed, For Comparative Evaluation Of The Pharmacokinetic And Pharmacodynamic Profile Of The Filgrastim Injectable Solution, In Relation To The Comparison Granulokine®, Ltda. After Subcutaneous Multiple Administration In Healthy Participants

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Megalabs · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will compare the pharmacokinetics and pharmacodynamics, after single subcutaneous application, in healthy men, between filgrastim formulation, produced by Megalabs (test product) and Granulokine® (reference product) Amgen.

Conditions

Interventions

TypeNameDescription
BIOLOGICALFilgrastim MegalabsFilgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
BIOLOGICALGranulokineGranulokine 5 μg/Kg/day, subcutaneous single dose

Timeline

Start date
2024-11-01
Primary completion
2025-04-30
Completion
2025-05-31
First posted
2021-07-12
Last updated
2024-08-16

Source: ClinicalTrials.gov record NCT04958772. Inclusion in this directory is not an endorsement.